90 related articles for article (PubMed ID: 12913085)
1. Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors.
Yamamoto N; Tamura T; Kamiya Y; Ono H; Kondoh H; Shirao K; Matsumura Y; Tanigawara Y; Shimada Y
Jpn J Clin Oncol; 2003 Jun; 33(6):302-8. PubMed ID: 12913085
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
3. A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.
Gadgeel SM; Boinpally RR; Heilbrun LK; Wozniak A; Jain V; Redman B; Zalupski M; Wiegand R; Parchment R; LoRusso PM
Invest New Drugs; 2003 Feb; 21(1):63-74. PubMed ID: 12795531
[TBL] [Abstract][Full Text] [Related]
4. A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
Weinstein SM; Abernethy AP; Spruill SE; Pike IM; True Kelly A; Jett LG
J Pain Symptom Manage; 2012 Apr; 43(4):679-93. PubMed ID: 21983265
[TBL] [Abstract][Full Text] [Related]
5. [Spicamycin derivative].
Mizumura Y
Nihon Rinsho; 2006 Feb; 64(2):322-8. PubMed ID: 16454188
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study.
Takama H; Tanaka H; Sudo T; Tamura T; Tanigawara Y
Cancer Chemother Pharmacol; 2001 May; 47(5):404-10. PubMed ID: 11391855
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Kurata T; Shimada Y; Tamura T; Yamamoto N; Hyodo I; Saeki T; Takashima S; Fujiwara K; Wakasugi H; Kashimura M
J Clin Oncol; 2000 Sep; 18(17):3164-71. PubMed ID: 10963645
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of the anticancer agent KRN5500 into polymeric micelles diminishes the pulmonary toxicity.
Mizumura Y; Matsumura Y; Yokoyama M; Okano T; Kawaguchi T; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2002 Nov; 93(11):1237-43. PubMed ID: 12460465
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
17. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors.
Catimel G; Coquard R; Guastalla JP; Merrouche Y; Le Bail N; Alakl MK; Dumortier A; Foy M; Clavel M
Cancer Chemother Pharmacol; 1995; 35(3):246-8. PubMed ID: 7805184
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
